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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.028The olfactomedin 4 (OLFM4) gene is located on chromosome 13q14.3, which frequently is deleted in
human prostate cancer. However, direct genetic evidence of OLFM4 gene alteration in human prostate
cancer has not yet been obtained. In this study, we investigated the genetics, protein expression, and
functions of the OLFM4 gene in human prostate cancer. We found overall 25% deletions within the OLFM4
gene in cancerous epithelial cells compared with adjacent normal epithelial cells that were microdissected
from 31 prostate cancer specimens using laser-capture microdissection and genomic DNA sequencing. We
found 28% to 45% hemizygous and 15% to 57% homozygous deletions of the OLFM4 gene via ﬂuores-
cence in situ hybridization analysis from 44 different prostate cancer patient samples. Moreover,
homozygous deletion of the OLFM4 gene signiﬁcantly correlated with advanced prostate cancer. By using
immunohistochemical analysis of 162 prostate cancer tissue array samples representing a range of
Gleason scores, we found that OLFM4 protein expression correlated inversely with advanced prostate
cancer, consistent with the genetic results. We also showed that a truncated mutant of OLFM4 that lacks
the olfactomedin domain eliminated suppression of PC-3 prostate cancer cell growth. Together, our
ﬁndings indicate that OLFM4 is a novel candidate tumor-suppressor gene for chromosome 13q and may
shed new light on strategies that could be used for the diagnosis, prognosis, and treatment of prostate
cancer patients. (Am J Pathol 2013, 183: 1329e1338; http://dx.doi.org/10.1016/j.ajpath.2013.06.028)Supported by the Intramural Research Program, NIH/National Institute
of Diabetes and Digestive and Kidney Diseases.Prostate cancer is the most commonly diagnosed solid tumor
and the second leading cause of cancer-related death in the
American male population.1 Loss of heterozygosity (LOH)
analyses of sporadic prostate cancers have provided evidence
for the existence of one or more tumor-suppressor genes
within chromosome 13q14’s cluster region.2e11 Several
candidate tumor suppressors are located there, including the
retinoblastoma susceptibility gene (RB1, 13q14.3), the breast
cancereassociated gene 2 (BRCA2, 13q12-13), and Forkhead
box O1 (FOXO1, 13q14), which encodes a transcription
factor of the Forkhead family.12 Each of these genes is
postulated to play a role in the progression of prostate
neoplasms5,7,11,13,14; however, it is not known if they repre-
sent all of the genes on chromosome 13q14 involved in
prostate cancer, or if others exist. Identiﬁcation and biological
evaluation of additional tumor-suppressor candidates in thisstigative Pathology.
.chromosomal region is important for a full molecular under-
standing of prostate cancer progression, with an ultimate goal
of improving diagnosis, prognosis, and treatment.
The olfactomedin 4 (OLFM4) gene, also known as human
granulocyte colony-stimulating factor-stimulated clone 1
(hGC-1), GW112, and human olfactomedin D (hOlfD), is
located on chromosome 13q14.3 and consists of ﬁve exons
spanning 23 kb in the human genome.15 OLFM4 mRNA is
expressed in normal human prostate tissue, but is reduced or
lost in advanced prostate cancer.16 The OLFM4 protein is an
olfactomedin domainecontaining family member17 that is
secreted into the serum18 aswell as included in the prostasomes
of semen.19 It regulates innate immunity in the mouse20 and
Li et alfacilitates cell adhesion via interaction with endogenous cell-
surface lectins and cadherins.21 The expression of OLFM4
protein is increased in well-differentiated gastric and colon
cancer, but is reduced or lost in poorly differentiated and
metastatic gastric and colon tumors.22,23We recently found that
ectopic expression ofOLFM4protein in humanprostate cancer
cells inhibits prostate cancer cell proliferation, invasion, and
metastasis through interaction with cathepsin D and stromal
cell-derived factor 1.16
In this study, we investigated genetic alteration of the
OLFM4 gene in human prostate cancer patients. We also
examined the expression pattern of OLFM4 protein in
human prostate cancer tissue arrays. We further determined
the effects of a truncated mutant of OLFM4 on OLFM4
protein functions, such as suppression of growth, induction
of autophagy, and inhibition of cathepsin D activity in PC-3
prostate cancer cells.
Materials and Methods
Human Prostate Tissue Specimens, Tissue Arrays, and
Cell Lines
Unstained whole-mount parafﬁn section slides were obtained
from the Laboratory of Pathology at the National Cancer
Institute (NIH, Bethesda, MD). For each case, a pathologist
(J.R.-C.) reviewed the whole-mount sections and selected
slides containing cancer and normal regions. Prostate cancer
tissue arrays were purchased from US Biomax (catalogue
number PR953; Rockville, MD) and Cybrdi (catalogue
number CC19-11-007; Rockville, MD). Frozen human pro-
state cancer tissues and matched normal tissues adjacent to
tumorswere obtained from surgically resectedmaterials at the
University of Pennsylvania Medical Center and the Cooper-
ative Human Tissue Network (Philadelphia, PA; Institutional
Review Board number 94-H-0010). Human normal prostate
epithelial cells, HPV-10, and RWPE-1 were purchased from
the American Type Culture Collection (Manassas, VA) and
were cultured in the recommended media. The benign and
malignant immortalized prostate cell lines RC170N, RC92,
and RC58 were obtained from Dr. Joghn Rhim’s laboratory
(Center for Prostate Disease Research, Uniformed Services
University of the Health Sciences, Bethesda, MD).24,25 The
human prostate cancer cell lines LNCaP, DU 145, VCaP, and
PC-3 were obtained from the American Type Culture
Collection and were maintained in RPMI 1640 medium with
10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA).
LCM
Laser capture microdissection (LCM) was performed using
an Arcturus Pix Cell II (Arcturus Engineering, Mountain
View, CA) as previously described.26 From a total of 31
cases, the microdissected normal and cancerous epithelial
cells were identiﬁed by a pathologist in the LCM core
facility (National Cancer Institute; NIH). Approximately133010,000 to 15,000 laser shots were used for each case to
procure the epithelial samples.
Genomic DNA puriﬁcation, PCR, and Sequencing
The genomic DNA of LCM samples was puriﬁed using
the QIAamp DNA Micro Kit (Qiagen, Germantown,
MD) following the manufacturer’s protocol. PCR was
performed on the genomic DNA to amplify ﬁve exons of
OLFM4 and microsatellite markers using the High-
Fidelity PCR kit (Invitrogen). The PCR products were
puriﬁed with the PCR puriﬁcation kit (Qiagen) and used
for DNA sequencing analysis (Euroﬁns MWG Operon,
Huntsville, AL).
PCR and sequencing primers for exons 1 to 5 of theOLFM4
gene are listed as follows: exon 1: PCR primers E1 forward: 50-
CAGCTCACTCACTGACAAGG-30, E1 reverse: 50-AG-
TGCCCATCCATGAAATTG-30 (PCR product 400 bp), E1
sequencing primer: 50-TACATGCTGGCCATGGGCTG-30;
exon 2: PCR primers E2 forward: 50-TTCGTACAACCAG-
TGGCGAT-30, E2 reverse: 50-ATGTCTTTGATGATTGC-
TTA-30 (PCR product 400 bp), E2 sequencing primer: 50-
GTAAGTACTCTCGACAAGCC-30; exon 2: PCR primers
E2_1 forward: 50-AGCTCAGATTCCAGCTTGTTA-30, E2_1
reverse: 50-ACGTGATGTCTTTGATAGTGA-30 (PCR pro-
duct 239 bp), E2_1 sequencing primer: 50-GACCTGCCA-
GTGCTCTGTTT-30; exon 3: PCR primers E3 forward: 50-
AATCTACCTCCCTTCAATTG-30, E3 reverse: 50-GTAC-
TAGTACTTGCTTACAGTC-30 (PCR product 400 bp), E3
sequencing primer: 50-AGTTCTCAACTCAAGGGCTC-30;
exon 4: PCR primers E4 forward: 50-CACACATCTGGA-
CAGGCATTC-30, E4 reverse: 50-CCACTCACAGCTCCTT-
ATGG-30 (PCR product 350 bp), E4 sequencing primer: 50-
CTCTGGTGTATTCTCTGGCA-30; exon 5: PCR primers E5
forward: 50-GAGACTGAATGCACTGAACTAAG-30, E5
reverse: 50-GTGGTAGAACTATGCACCTA-30 (PCR product
950 bp), E5_1 sequencing primers: 50-ATCAGAACCACT-
GTTGTTAT-30, E5_2: 50-AGATATCTAAGTAAGTGGAG-
30, E5_3: 50-CACGATTGCTGTGACTCAAA-30, E5_4: 50-
TATCTTGCCAAGCAACATTA-30; exon 5: PCR primers
E5_1 forward: 50-ATAACGATGGTTACCTTCTGA-30, E5_1
reverse: 50-GTGGTAGAACTATGCACCTA-30 (PCR product
188 bp), exon 5: PCR primers E5_2 forward: 50-GAGACT-
GAATGCACTGAACTAAG-30, E5_2 reverse: 50-TCTCC-
AGTTGAGCTGAACCACAG-30 (PCR product 243 bp).
Chromosome 13q microsatellite marker primers are listed as
follows: D13S1317 forward: 50-CTTGGAAACCAACAAG-
TCAC-30, D13S1317 reverse: 50-ATTTTGCCACCTAGAA-
CGG-30 (PCR product 223 bp); D13S275 forward: 50-
TTGTGCAGGGCATCAAC-30, D13S275 reverse: 50-TGC-
TTCCAAGAATTTGGCTA-30 (PCR product 239 bp);
D13S1260 forward: 50-GTGAGTCATTCAAGCCGTTA-30,
D13S1260 reverse: 50-AAAATACATGGTGCTGCTTC-30
(PCR product 141 bp); D13S1310 forward: 50-TTGATTGCT-
TACTATAAACCAGG-30, D13S1310 reverse: 50-GGGAAA-
ACATCTAGTGAAACA-30 (PCR product 143 bp).ajp.amjpathol.org - The American Journal of Pathology
OLFM4 and Prostate Cancer ProgressionOLFM4 FISH Analysis
The triple- or dual-color ﬂuorescence in situ hybridization
(FISH) strategy was used on prostatic adenocarcinoma tissue
microarrays, using four bacterial artiﬁcial chromosome
(BAC) clones spanning both OLFM4 genomic regions and
the RB1 gene locus, as well as a commercially available DNA
probe for region 13q34 (612 kb) (Vysis LSI 13q34 Spec-
trumGreen probe; Abbott Molecular, Desplaines, IL). The
BAC clones were the OLFM4 gene locus located at 13q14.3
(52500972 to 52524189): RP11-778G13 (52399270 to
52582284), RP11-137D14 (52468911 to 52603231), and
RP11-828P8 (52516176 to 52691316), and the RB1 gene
locus located at 13q14.3 (47775883 to 47954027): RP11-
10001I7 (47767794 to 47957185). The positions and names
of the BAC clones were taken from the Human March 2006
assembly of the University of California, Santa Cruz (UCSC)
Genome Browser 1 (http://genome.ucsc.edu). The presence
of OLFM4 and RB1 sequences and the correct chromosome
location of the BAC clones were veriﬁed by PCR and by
hybridization to metaphase spreads from normal peripheral
lymphocytes, respectively. BAC DNA was extracted and
labeled with Spectrum Green-deoxyuridine 50-triphosphate,
Red 5-ROX-deoxyuridine 50-triphosphate, or Gold 5(6)-car-
boxyrhodamine 6G-deoxyuridine 50-triphosphate using the
nick-translation kit (Empire Genomics, Buffalo, NY). An
Olympus BX61 microscope with an Olympus U-CMAD3
camera (Center Valley, PA) andBioview software version 3.4
operation systems (Billerica, MA) were used to capture the
images.
Production of PC-3 Cell Clones
Plasmid constructs for truncated OLFM4 have been
described previously.21 PC-3 cells were transfected with
pcDNA3.1/vector, pcDNA3.1-Flag-hGC-1, or its truncated
mutant using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. The cells then were cultured
in the presence of 400 mg/mL G418 (Invitrogen) to establish
stable cell lines.
Immunohistochemistry of OLFM4
We previously generated anOLFM4 polyclonal antibody and
have used it in immunohistochemistry and Western blotting
analyses of tumor cells and human tissues.22,23 Preparation of
tissue sections for immunostaining has been described
previously.27 Tissue sections were incubated with OLFM4
antibody diluted 1:500 in 1%bovine serum albumin, followed
by biotinylated goat anti-rabbit secondary antibody (Bio-
genex, San Ramon, CA) and streptavidinehorseradish-
peroxidase complex (Biogenex). The brown color was
developed using 3,30-diaminobenzidine (Biogenex) and
counterstained with Mayer’s hematoxylin (Sigma-Aldrich,
St. Louis,MO). Individual prostate specimenswere scored for
expression of OLFM4 at three semiquantitative levels ofThe American Journal of Pathology - ajp.amjpathol.orgincreasing staining intensity: undetectable, 0; low immuno-
staining, 1þ; and intermediate to strong immunostaining, 2þ
to 3þ.
Colony Formation in Soft Agar
A suspension (1  104 cells/mL) in 2 mL of 0.35% Noble
agar with RPMI 1640 and 10% FBS was overlaid into 6-
well plates containing a 0.6% agar base. Each experiment
was performed in triplicate and colonies larger than 0.1 mm
in diameter were counted and recorded after culturing for
2 weeks.28,29
Autophagy Assays
PC-3 cell clones were grown in T75 ﬂasks in RPMI 1640 plus
10% heat-inactivated FBS. The analysis of autophagy was
performed following the procedure described previously.16
For Western blots, cell lysates were separated using 4% to
12% polyacrylamide gel electrophoresis, transferred to
a polyvinylidene ﬂuoride membrane, and hybridized with
a rabbit monoclonal antibody for microtubule-associated
protein 1 light chain 3 B (LC3B) (D11), a cathepsin D poly-
clonal antibody that recognizes both full-length and cathepsin
D active form, or a b-actin polyclonal antibody (Cell
Signaling Technology, Danvers, MA) at 1:1000, and then
developed as described previously.16 For ﬂow cytometry,
cells were serum-starved for 3 days, exposed to 1 mg/mL
acridine orange (Sigma-Aldrich) for 20 minutes, trypsinized,
and resuspended in PBS. Approximately 10,000 cells were
analyzed using the CD13-PE channel of a BD FACSCalibur
ﬂow cytometer (BD, Franklin Lakes, NJ). For immunohis-
tochemistry analysis, the cells were grown on tissue culturee
treated chamber slides (BD). To detect autophagosomes, cells
were analyzed by immunohistochemistry using the D11
LC3B antibody (1:200 dilution). All images were acquired
using an Olympus BX51 microscope and Qimaging Camera
with Q Capture pro software version 6.0 (Qimaging, Surrey,
British Columbia, Canada). Images were acquired using the
20 Uplan Apo objective (Olympus, Center Valley, PA) and
then imported into Adobe (San Jose, CA) Photoshop for
presentation.
Co-Immunoprecipitation Analysis
Vector-transfected control clone (PC-3V), full-length
OLFM4-expressing clone (PC-3W), and truncated mutant
of OLFM4-expressing clone (PC-3N) cells were cultured in
RPMI 1640 containing 10% FBS medium until 90%
conﬂuent. The cells were harvested and lysed in lysis buffer
for immunoprecipitation.27 These lysates (500 mg in 0.5
mL) were mixed with 2 mg of antibody to Flag (Sigma) or
cathepsin D, and then incubated for 3 hours at 4C. After
this incubation, 100 mL of rec-protein GeSepharose 4B
conjugate (10-1241; Invitrogen) was added and incubated
with mixing overnight at 4C. After centrifugation at 30001331
Li et al g for 1 minute, supernatants were aspirated and discarded.
Pellets were washed in lysis buffer three times for 15
minutes. Thirty microliters of sample buffer was added to
the agarose pellets, which then were boiled for 10 minutes.
Samples were separated using 4% to 12% polyacrylamide
gel electrophoresis, transferred to a polyvinylidene ﬂuoride
membrane, hybridized with 1:500 antiecathepsin D or13321:1000 anti-Flag antibody, and then developed as described
previously.16
Cathepsin D Activity Assay
The cathepsin D assay kit was purchased from Sigma-
Aldrich and cathepsin D activity assays were performed
according to the manufacturer’s instructions. To detect
cathepsin D activity in the conditioned media of PC-3
cell clones, 1  106 cells/well were plated into 6-well
plates. The cells were cultured in RPMI 1640 contain-
ing 10% FBS overnight, then changed into serum-free
RPMI 1640. The conditioned media were harvested
after culturing for 48 or 72 hours, and then concentrated
with Amicon Ultra 0.5 mL 3K centrifugal ﬁlter units
(Millipore, Billerica, MA). For preparing cell lysates, cell
pellets were washed with ice-cold PBS and were lysed
with cell lysis buffer (CytoBuster protein extraction
reagent, catalogue number 71009; Millipore). The total
protein concentration of cell lysates was measured using
the Micro BCA Protein Assay Kit (Thermo Scientiﬁc,
Rockford, IL). Cathepsin D activities were measured with
10 mg of total protein for each reaction and 20 mmol/L of
the substrate MCA_Gly-Lys-Pro-IIe-Leu-Phe-Phe-Arg-
Leu-Lys (DNP) D-Arg-NH2 triﬂuoroacetate salt in
a 100-mL reaction solution at pH 4.0 and 25C. The reaction
process was monitored continuously for 45 minutes with
product (7-methoxycoumarin-4 acetic acid) on a FLUOstar
Optima Fluorimeter (BMG, Cary, NC) with 320-nm exci-
tation and 410-nm emission wavelength ﬁlters.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
5.0 software (La Jolla, CA) or SAS software version 9.1
(Cary, NC). The data were analyzed by analysis of variance,
the Tukey-Kramer honestly signiﬁcant difference test for
FISH data, or the Spearman rank-order correlation co-
efﬁcient for OLFM4 expression versus the Gleason score.
A P value of less than 0.05 was considered statistically
signiﬁcant.Figure 1 Genomic analysis of OLFM4 in the LCM samples of human
prostate specimens. A: Representative images of H&E-stained sections and
matched sections immunohistochemically stained with OLFM4 antibody
from paired adjacent normal prostate and prostate cancer foci in specimens
for patient P1. Scale bar Z 100 mm. B: LOH of the OLFM4 gene at
rs2298231(S118S) within exon 2 of OLFM4 in prostate cancer. The se-
quencing chromatogram images are shown in the paired normal and cancer
cells from patients P1, P6, and P17. Asterisks indicate rs2298231C/T
(S118S) position. C: Ampliﬁcation of 2 exons of the OLFM4 and b-actin
gene (ACTB) by PCR using patient genomic DNA samples from LCM-prepared
prostate cancer epithelial cells. Bands represent genomic DNA-PCR products
of exon 2 (E2, 239 bp) and exon 5 [E5, 243 bp (168 bp from intron 4 and 75
bp from exon 5) and E5, 188 bp within exon 5]. The patient DNA samples
were named as P numbers. N, normal; T, tumor; PC, positive control DNA;
H20, water negative control. D: Summary of PCR results from four patients.
Hatched and ﬁlled circles indicate hemizygous and homozygous deletions,
respectively. Open circles indicate two retained alleles.
ajp.amjpathol.org - The American Journal of Pathology
Figure 2 FISH analysis of OLFM4 in different Gleason scores of prostate
cancer tissue arrays. A: Representative images of hemizygous and homozygous
deletionofOLFM4 in prostate cancer tissueswith aGleason score of 7 and10. The
red color probe was used for OLFM4 and the green color probe was used for LSI
13q34. Tumor cells with one red signal and two green signals represent a hemi-
zygousdeletionof theOLFM4 locus in tissuewith aGleason score of 7. Tumor cells
withno red signals and twogreen signals represent ahomozygousdeletionof the
OLFM4 locus in tissue with a Gleason score of 10. B: Pie chart illustrating the
mean percentage of cancer cells with OLFM4 deletions in human prostate cancer
specimens with different Gleason scores (Gl.). Blue areas, percentage of hemi-
zygous deletion; red areas, percentage of homozygous deletion; green areas,
percentage of undeleted OLFM4. C: The scatter plot graph represents the
percentage of homozygous deletions in individual samples of human prostate
cancer specimens with different Gleason scores. *P < 0.05, ***P < 0.001.
Table 1 Summary of OLFM4 Expression, SNP, and Deletion Data for Human Patient Samples
Expression of OLFM4 SNP (rs2298231) Deletion Methods
Normal or adjacent
normal (31)
100% (31/31) 32% (10/31) None LCM and PCR
sequencing
Tumor (31) 26% (8/31) 29% (9/31) 25% (4/16*)
Tumor (44, tissue array)
Gleason score
46 (11) 54% (6/11) NA Hemizygous, 31%; homozygous, 15% FISH
7 (13) 38% (3/13) NA Hemizygous, 45%; homozygous, 33%
810 (20) 25% (4/20) NA Hemizygous, 28%; homozygous, 57%
Prostate tissues (frozen)
Normal (6) 100% (6/6) 17% (1/6) None PCR and sequencing
Tumor (8) 38% (3/8) 50% (4/8) 25% PCR and sequencing
*Sixteen samples returned informative sequencing results.
NA, not available.
OLFM4 and Prostate Cancer ProgressionResults
The OLFM4 Gene Is Frequently Deleted in Human
Prostate Cancer
To investigate genetic alterations of the OLFM4 gene in
human prostate cancer, we searched microsatellite markers
ﬂanking the OLFM4 gene in chromosome 13q and designed
primers for exons 1 to 5. We ﬁrst performed PCR with
genomic DNA for exons 1 to 5 of theOLFM4 gene in normal,
benign, and malignant prostate cell lines (Supplemental
Figure S1, AeC). Single-nucleotide polymorphisms (SNPs)
of OLFM4 are summarized at the National Center for Bio-
technology Information (NCBI) Single Nucleotide Poly-
morphism database (dbSNP) website (http://www.ncbi.nlm.
nih.gov/projects/SNP/snp_ref.cgi?geneidZ10562). The
minor allele frequency of rs2298231 within exon 2 is 0.4441,
which is the highest frequency SNP site identiﬁed in the
population examined. We also found SNP at rs2298231
within exon 2 (S118S) in the caseswe studied (Figure 1,A and
B, Table 1, and Supplemental Figure S1, D and E). SNP was
observed in normal prostate epithelial cells and two immor-
talized primary tumor cell lines (Supplemental Table S1).
Expression of OLFM4 was detected only in normal prostate
epithelial cells and in two immortalized primary normal cell
lines (Supplemental Table S1). Deletion of OLFM4 in DU
145 cells was detected byPCR (Supplemental Figure S1C and
Supplemental Table S1) and FISH analysis (Supplemental
Figure S2).
We next examined the expression of OLFM4, SNP, and
deletion results for normal and cancerous epithelial cells from
human prostate cancer specimens prepared using LCM
(summarized in Table 1). OLFM4 protein was highly
expressed in adjacent normal acinar epithelial cells, whereas
expression was reduced or lost in the tumor foci acinar
epithelial cells (Figure 1A and Table 1). Genomic DNA was
extracted from adjacent normal and tumor epithelial cells,
and the ﬁve exons of the OLFM4 gene were ampliﬁed by
PCR and sequenced. Genomic DNA sequencing results
showed SNP and 25% LOH at rs2298231 within exon 2 of
OLFM4 in prostate cancer patient specimens (Figure 1B andThe American Journal of Pathology - ajp.amjpathol.orgTable 1). The SNP and LOH at rs2298231 also were detected
in frozen prostate cancer tissues (Table 1). Moreover, small-
region deletion of exon 5 within OLFM4 was observed in the
tumor foci of three patients (P19, P20, and P29) by PCR
(Figure 1C). Large-region deletion of OLFM4 was detected1333
Figure 3 OLFM4 protein expression is reduced
or lost in advanced human prostate cancer. A:
Representative images of OLFM4 immunohisto-
chemical staining of prostate cancer tissue arrays
(Cybrdi). Individual prostate specimens were scored
for expression of OLFM4 at three semiquantitative
levels of increasing staining intensity. Positive
staining was scored as 1þ, stronger staining was
scored as 2þ to 3þ, and negative staining was
scored as 0. Scale bar Z 100 mm. B: Relationship
between OLFM4 protein expression and Gleason
score. The bar graph represents the percentage of
tissues in a Gleason grading group that were scored
for OLFM4 protein expression as 2þ to 3þ as
described in panel A. C: The relationship between
loss of OLFM4 protein expression and Gleason
score. The bar graph represents the percentage of
tissues in a Gleason grading group that were scored
for OLFM4 protein expression as 0 as described in
panel A. The data represent 162 prostate cancer
tissue array specimens: n Z 55 for tissues with
a Gleason score of 4 to 6; n Z 36 for tissues with
a Gleason score of 7; and nZ 71 for tissues with a
Gleason score of 8 to 10 (B and C).
Table 2 Relationship Between OLFM4 Expression and Gleason
Score in Prostate Cancer Tissue Array Samples
Gleason score
OLFM4 expression
2þ to 3þ 1þ 0 n
46 31 18 6 55
7 15 13 8 36
810 5 26 40 71
n 51 57 54 162
The Spearman rank-order correlation coefﬁcient for OLFM4 expression
versus Gleason score was P < 0.001.
Li et alin patients P19 and P20 and conﬁrmed by FISH analysis
(Figure 1D and Supplemental Figure S3). The microsatellite
markers near OLFM4 remained unchanged in the patient
samples studied (Figure 1D). These results showed the small
and/or large deletion of the OLFM4 gene in the tumor foci of
prostate cancer patient samples.
Homozygous Deletion of the OLFM4 Gene Is Correlated
with Advanced Human Prostate Cancer
Because these ﬁndings were consistent with the loss of one
or both copies of the OLFM4 gene in prostate tumor foci,
we next used FISH analysis to examine the deletion status of
OLFM4 in human prostate cancer in a new set of patient
cases available in prostate cancer tissue arrays.
We ﬁrst designed and veriﬁed an OLFM4 FISH probe by
performing triple-color FISH with control metaphase cells
using OLFM4, RB1, and LSI 13q34, a control probe that
recognizes a 612-kb region of 13q34 (Supplemental
Figure S4A). Hemizygous and homozygous deletions1334of OLFM4 were observed in primary tumor regions
(Supplemental Figure S4B). To examine more primary
tumor tissues, we performed FISH analysis in specimens with
Gleason scores of 4 to 6, 7, and 8 to 10 from prostate cancer
tissue array samples (Table 1 and Figure 2A). Collectively,
we observed 28% to 45% hemizygous deletion and 15% to
57% homozygous deletion in the 44 prostate cancer speci-
mens (Figure 2A and Table 1). In detail, we observed a meanajp.amjpathol.org - The American Journal of Pathology
Figure 4 Truncated mutant of the OLFM4 gene
loses its ability to inhibit cell growth and induce
autophagy in PC-3 cells. A: Schematic illustration of
full-length (OLFM4-W) and truncatedmutant (OLFM4-
N, deletion of olfactomedin domain) OLFM4 con-
structs. Ser-rich domain (31e71aa), coiled-coil
domain (155e234aa), and olfactomedin domain
(245e507aa) are represented with light blue, red,
and green segments, respectively. B: Expression of
OLFM4-W and OLFM4-N in the PC-3 cell clones
detected using Western blot analysis with anti-Flag
and anti-actin antibodies. b-actin is presented as
a loading control. C: Colony-formation assays per-
formed with PC-3 cell clones in soft agar. The images
show colonies after culture for 14 days and the bar
graph shows the mean colony number (means  SD,
nZ 3). V, PC-3V (vector-transfected control) clone;
W, PC-3W (full-length OLFM4-expressing) clone; N,
PC-3N (truncatedmutant ofOLFM4-expressing) clone.
D: Representative images of immunohistochemical
staining with LC3B antibody in the PC-3 cell clones.
Arrows indicate autophagic cells. E: Western blot
analysis of LC3B protein in the PC-3 cell clones. b-
actin is presented as a protein loading control. F:
Detection of autophagic cells using ﬂow-cytometry
analysis. PC-3V, PC-3W, and PC-3N cells were grown
in RPMI 1640 medium without serum for 3 days and
stained with 1 mg/mL acridine orange for 20minutes.
Approximately 10,000 cells were analyzed using the
CD13-PE channel of a BD FACSCalibur ﬂow cytometer.
A representative proﬁle from ﬂow-cytometry analysis
is shown (nZ 3) (left panel). The mean percentage
of acridine orangeestaining cells (means SD, nZ
3) obtained by ﬂow-cytometry analysis is presented
in the bar graph (right panel). *P < 0.05, **P <
0.01. Scale bars: 200 mm (C); 50 mm (D).
OLFM4 and Prostate Cancer Progressionof 31% hemizygous deletions and 15% homozygous dele-
tions of OLFM4 in tissues with a Gleason score of 4 to 6,
a mean of 45% hemizygous deletions and 33% homozygous
deletions of OLFM4 in tissues with a Gleason score of 7, and
a mean of 28% hemizygous deletions and 57% homozygous
deletions ofOLFM4 in tissues with a Gleason score of 8 to 10
(Figure 2B). The percentage of homozygous deletions of
OLFM4 was associated signiﬁcantly with the Gleason score
of the prostate cancer tissues (Figure 2C). These results
suggest that loss of OLFM4 is correlated with progression of
prostate cancer.
Loss of OLFM4 Protein Expression Is Correlated with
Advanced Human Prostate Cancer
Because we have previously reported that expression of
OLFM4 mRNA is reduced or lost in advanced prostate
cancer and prostate cancer cell lines,16 in this study we
examined OLFM4 protein expression in tissue arrays
containing 162 different prostate cancer samples repre-
senting Gleason scores of 4 to 6, 7, and 8 to 10. OLFM4
protein was highly expressed in the cytoplasm of acinar
epithelial cells (score, 3þ), was heterogenous in well-
differentiated and intermediately differentiated tumor
tissues (score, 2þ), and was reduced (score, 1þ) or lostThe American Journal of Pathology - ajp.amjpathol.org(score, 0) in the tumor loci acinar epithelial cells
(Figure 3A). The percentage of tissues with highly
expressed OLFM4 was reduced substantially in the spec-
imens with Gleason scores of 7 and 8 to 10 (Figure 3B).
Interestingly, OLFM4 protein expression was lost in 11%
(6 of 55) of well-differentiated prostate cancer specimens
(Gleason score, 4 to 6), in 22% (8 of 36) of intermediately
differentiated prostate cancer specimens (Gleason score,
7), and in 56% (40 of 71) of advanced prostate cancer
specimens (Gleason score, 8 to 10) (Figure 3C). Loss of
OLFM4 protein expression was associated signiﬁcantly
with a higher Gleason score for prostate cancer tissues
(Table 2) (P < 0.001). These results suggest that loss of
OLFM4 protein expression is correlated with the pro-
gression of prostate cancer.The Truncated Mutant of the OLFM4 Gene Is Unable to
Inhibit Growth and Induce Autophagy in PC-3 Prostate
Cancer Cells
Exon 5 of theOLFM4 gene encodes the olfactomedin domain
of the OLFM4 protein. In this study, we observed the deletion
of a small region of exon 5 in prostate cancer tumor foci
(Figure 1, C and D). Because we previously have found that1335
Figure 5 Olfactomedin domain of the OLFM4 gene is essential for
blocking cathepsin D activity. A: Co-immunoprecipitation of the truncated
mutant of OLFM4 protein and cathepsin D in the cell lysates of PC-3V and
PC-3N cell clones. The PC-3W cells are shown as a control. n, negative
control with normal IgG; p, positive control. B: Cathepsin D activity at each
time point is shown in the cell lysates and conditioned media of PC-3V, PC-
3W, and PC-3N cell clones at 72 hours. Data at each time point are
expressed as means  SD. C: Cathepsin D activity in the conditioned media
of PC-3V, PC-3W, and PC-3N cell clones. The conditioned media were har-
vested after cells were cultured for 48 or 72 hours in serum-free medium.
Cathepsin D activity at 25 minutes was measured. Data are expressed as
means  SD. *P < 0.01 (n Z 3).
Li et alectopic expression of theOLFM4 gene in PC-3 cells inhibited
growth of cells through increased autophagy,16 we examined
whether deletion of exon 5 in the OLFM4 gene would affect
the function of the OLFM4 protein, causing PC-3 cells to lose
their ability to inhibit cell growth and induce cellular auto-
phagic function. We generated stably expressing PC-3 cell
clones (PC-3N) carrying an olfactomedin domainetruncated
mutant of the OLFM4 gene (Figure 4A). OLFM4-N mutant
protein was detected in PC-3N cell clones by Western blot
analysis (Figure 4B). PC-3N cells displayed increased colony
formation compared with PC-3V, whereas PC-3W inhibited
colony growth (Figure 4C). Ectopic expression of theOLFM4
gene induced autophagy as detected with LC3B antibody
immunoﬂuorescent staining (Supplemental Figure S5).
PC-3N cells had substantially reduced levels of cellular
autophagy compared with PC-3W cells, as determined by
LC3B immunohistochemistry (Figure 4D) and Western blot
(Figure 4E). After serum starvation for 3 days, the percentage
of autophagic cellswas increased signiﬁcantly in PC-3Wcells
comparedwith PC-3V cells, whereas the percentage remained
unchanged in PC-3N cells (Figure 4F). We also analyzed
autophagic cells after amino acid starvation for 0.5, 1, and 2
hours and found a signiﬁcantly increased number of auto-
phagic cells in the PC-3W but not the PC-3N cultures after
starvation for 0.5 hours when compared with PC-3V cells
(Supplemental Figure S6). Our results indicate that the loss of
the olfactomedin domain in an OLFM4 gene mutant resulted
in the loss of its ability to suppress tumor cell growth.
The Truncated Mutant of the OLFM4 Gene Is Unable to
Inhibit Cathepsin D Activity in PC-3 Prostate Cancer
Cells
We previously found that OLFM4 protein physically inter-
acts with cathepsin D, and that ectopic expression of
OLFM4 protein inhibits cathepsin D catalytic activity in the
prostate cancer cell lines PC-3, LNCaP, and DU 145.16 In
this study, we examined if the truncated mutant of OLFM4
protein lacking the olfactomedin domain could eliminate the
ability of OLFM4 protein to inhibit cathepsin D activity.
Co-immunoprecipitation assays showed that the truncated
mutant of OLFM4 protein interacted with cathepsin D
protein in the PC-3N cells (Figure 5A). However, although
cathepsin D activity signiﬁcantly was inhibited in the PC-
3W cells expressing full-length OLFM4 protein, the
cathepsin D activity of PC-3N cells expressing the truncated
mutant of OLFM4 was similar to that of control PC-3V cells
(Figure 5, B and C). These results suggest that the olfac-
tomedin domain of OLFM4 protein is essential for its
inhibition of cathepsin D activity.Discussion
Deletion at 13q14 is common in many cancers, including
prostate cancer. Although FOXO1 and RB1 have been1336identiﬁed as candidate tumor-suppressor genes at 13q14,
identiﬁcation and biological evaluation of additional tumor-
suppressor candidates in this chromosomal region is impor-
tant for a full molecular understanding of prostate cancer
progression. The data presented in this article show that
OLFM4 is a novel candidate for a 13q14 tumor-suppressor
gene. We report for the ﬁrst time that deletion of OLFM4 is
associated with progression of human prostate cancer. We
also found that the expression pattern of OLFM4 protein is
correlated inversely with progression of prostate cancer, in
agreement with our OLFM4 deletion data. Ectopic expres-
sion of full-length OLFM4 or an OLFM4-truncated mutant
that lacks the olfactomedin domain in PC-3 cells showed that
the olfactomedin domain of the OLFM4 protein is necessary
for OLFM4’s suppression of PC-3 cell growth.
The OLFM4 gene consists of ﬁve exons spanning 23 kb
and is located at chromosome 13q14.3, adjacent to tumor
suppressor RB1.15 Numerous studies have identiﬁed the
existence of a prostate cancer tumor-suppressor gene on
chromosome 13q14.3 within the LOH cluster region, with
the reported frequency of LOH ranging from 32% to
85%.2e11 Overall, we found 28% to 45% hemizygous andajp.amjpathol.org - The American Journal of Pathology
OLFM4 and Prostate Cancer Progression15% to 57% homozygous deletions of the OLFM4 gene in
prostate cancer tumors with Gleason scores of 4 to 6, 7, and
8 to 10. Genomic DNA sequencing results showed SNPs at
rs2298231 (S118S) within OLFM4 exon 2 in both prostate
cancer cell lines and patient specimens, and 25% LOH at
rs2298231 in exon 2 in epithelial cells microdissected from
prostate cancer specimens. Genomic DNA PCR results
showed deletion of OLFM4 exon 5 in the prostate cancer
loci of three patients. These ﬁndings indicate that somatic
deletion at OLFM4 is frequent in human prostate cancer.
Importantly, FISH analysis showed that homozygous dele-
tion of the OLFM4 gene is associated with high Gleason
scores for prostate cancer. Our results imply that OLFM4
may play an important role in the suppression of prostate
cancer progression.
Down-regulation of OLFM4 mRNA expression has been
reported in advanced prostate cancer, colorectal cancer, and
advanced gastric cancer.16,22,23 The OLFM4 protein ex-
pression patterns we observed are consistent with reported
OLFM4 mRNA levels in prostate cancer cells16 and corre-
lated with OLFM4 deletion status in the prostate cancer
samples studied here. OLFM4 protein is highly expressed in
normal and adjacent normal acinar epithelial cells, whereas it
is reduced or lost in tumor loci acinar epithelial cells. The
reduction or loss of OLFM4 protein expression is associated
with high Gleason scores for prostate cancer, implying that
OLFM4 protein can be used as a marker for predicting pros-
tate cancer progression.
OLFM4 is a secreted glycoprotein and has a multimer
structure, as do other olfactomedin domain-containing
proteins.17 It has been reported that serine-rich, coiled-coil,
and olfactomedin domains of OLFM4 act to promote olig-
omer formation, secretion, and interaction with other proteins
and participate in regulating cellular functions.21 We previ-
ously reported that OLFM4 protein interacts with cathepsin
D and SDF1 and negatively regulates cathepsin D and SDF1
biological functions in PC-3 prostate cancer cells.16 We have
shown here that these functions of the OLFM4 protein
require full-length OLFM4 protein. We found that although
the truncated mutant of OLFM4 protein was able to interact
with cathepsin D, loss of the olfactomedin domain in this
mutant eliminated its ability to block cathepsin D catalytic
activity, induce autophagy, or suppress PC-3 cell growth.
Thus, deletion within exon 5 of the OLFM4 gene in prostate
cancer patients also results in loss of functions for the
OLFM4 protein. Cathepsin D plays an important role in the
regulation of tumor cell proliferation and metastasis.30 The
alterations of cathepsin D activity may affect PC-3 tumor cell
proliferation.16 Therefore, loss of OLFM4 may accelerate
malignant progression of human prostate cancer. Currently,
we are examining an Olfm4 knockout mouse model to better
understand the physiological role and molecular pathways
involved in Olfm4 function in the murine prostate.
OLFM4 is involved in multiple biological processes,21
inﬂammatory disease,20,31,32 and cancers.16,22,23,33,34 It previ-
ously was reported that OLFM4 was involved in autophagy inThe American Journal of Pathology - ajp.amjpathol.orgPC-3 cells.16 Autophagy also has been proposed as a tumor-
suppressor mechanism.35 Autophagic cell death is a type II
programmed cell death that has been reported to suppress
tumor progression.36 We previously found that ectopic
expression of the OLFM4 gene in PC-3 cells signiﬁcantly
increased autophagic cells, perhaps through physical interac-
tion with cathepsin D.16 Cathepsins are lysosomal proteinases
and play a number of important roles underlying physiological
and pathologic conditions.37,38 In particular, cathepsin D has
been shown to be involved in cancer cell proliferation, inva-
sion, and metastasis.30 Interestingly, our results reported here
indicate that the olfactomedin domain of the OLFM4 protein is
necessary for OLFM4 to inhibit cathepsin D autocatalytic
activities and increasePC-3 cell autophagic death.Ourﬁndings
here indicate that an olfactomedin domainetruncated mutant
of the OLFM4 gene eliminates tumor-suppressor function,
perhaps because cathepsin D affects cellular autophagy in the
PC-3 cells.
Taken together, our results suggest that the OLFM4 gene
may play an important tumor-suppressor role in the
progression of prostate cancer. Our ﬁndings provide a novel
molecular tool for improving prostate cancer prognostic and
therapeutic approaches.
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